The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Machine learning-based risk score for predicting atrial fibrillation in pts with CLL on BTKi therapy
BTK inhibitors (BTKis) are being increasingly used for the treatment of chronic lymphocytic leukemia (CLL); however, a common side effect of these agents is atrial fibrillation. In this video, Tamar Tadmor, MD, Bnai Zion Medical Center, Haifa, Israel, shares insights into a machine learning-based risk score that has been developed to identify patients at risk of developing atrial fibrillation when treated with these agents. This system is the first to incorporate first- and second-generation BTKis alongside a machine learning approach, which integrates a variety of parameters to generate risk scores for patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
